CHANGMAO BIO announced its interim results, with a loss attributable to shareholders of 25.79 million yuan, an increase of 37.28% year-on-year
I'm PortAI, I can summarize articles.
CHANGMAO BIO announced its mid-year results for 2025, with revenue of approximately 272 million yuan, a year-on-year decrease of 13.23%; the loss attributable to shareholders of the company was 25.79 million yuan, a year-on-year increase of 37.28%; the loss per share was 0.049 yuan. The decline in performance was mainly affected by external factors such as geopolitical conflicts and uncertainty in tariff policies, as well as lower-than-expected demand for downstream products of maleic anhydride and increased interest expenses
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments